Overview

A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

Status:
COMPLETED

Trial end date:
2023-11-13

Target enrollment:

Participant gender:

Summary

The purpose of this study was to assess the safety and tolerability of RO7200220 as monotherapy (diabetic macular edema \[DME\] or uveitic macular edema \[UME\] population) and in combination with ranibizumab (DME population only).

Phase:

PHASE1

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Ranibizumab